可溶性鸟苷酸环化酶激动剂治疗HFrEF的疗效及对心肺运动试验参数的影响研究  

Study on the therapeutic effect of soluble guanylate cyclase agonist on HFrEF and its impact on cardiopulmonary exercise test parameters

作　　者：周小钰 夏碧桦 杨菲 喻川 韩莎 ZHOU Xiao-yu;XIA Bi-hua;YANG Fei(Department of Cardiology,The Second Affiliated Hospital of Guizhou Medical University,Kaili 556000,China)

机构地区：[1]贵州医科大学第二附属医院心血管内科,556000

出　　处：《中国现代药物应用》2025年第4期107-110,共4页Chinese Journal of Modern Drug Application

基　　金：贵州省卫生健康委科学技术基金项目(项目编号:2024GZWJKJXM0117)。

摘　　要：目的 探究可溶性鸟苷酸环化酶激动剂(维立西呱片)治疗射血分数降低的心力衰竭(HFrEF)的疗效及对心肺运动试验参数的影响。方法 选取100例HFrEF患者作为研究对象,基于随机数字表法将患者分为观察组与对照组,各50例。对照组给予常规治疗,观察组给予常规治疗+维立西呱片治疗。比较两组患者治疗效果,心肺运动试验参数[最大摄氧量(VO_(2max))、无氧阈值(AT)和峰值氧脉搏(Peak VO_(2)/HR)],心功能[左心室射血分数(LVEF)、N末端B型利钠肽前体(NT-proBNP)、左心室舒张末期内径(LVEDD)],不良事件发生情况。结果 治疗后,观察组患者治疗总有效率96.00%(48/50)明显高于对照组的78.00%(39/50),有显著性统计学差异(P<0.05)。治疗后,观察组患者VO_(2max)(22.26±1.41)ml/(kg·min)、AT(869.37±102.64)ml/min高于对照组的(17.32±1.18)ml/(kg·min)、(735.41±86.25)ml/min,Peak VO_(2)/HR(8.93±0.76)ml/beat低于对照组的(11.34±1.02)ml/beat,有显著性统计学差异(P<0.05)。观察组患者治疗后LVEF(48.94±3.53)%明显高于对照组的(42.15±3.44)%,NT-proBNP(1145.47±85.02)pg/ml、LVEDD(51.54±7.19)mm均明显低于对照组的(1896.16±93.14)pg/ml、(57.15±7.76)mm,有显著性统计学差异(P<0.05)。观察组不良事件发生率4.00%(2/50)明显低于对照组的18.00%(9/50),有显著性统计学差异(P<0.05)。结论 在HFrEF治疗中,可溶性鸟苷酸环化酶激动剂维立西呱用药效果显著,可有效改善患者的心肺运动试验参数、心功能水平,且用药安全,值得推广应用。Objective To explore the therapeutic effect of soluble guanylate cyclase agonist(vericiguat tablets)on heart failure with reduced ejection fraction(HFrEF)and its impact on cardiopulmonary exercise test parameters.Methods 100 HFrEF patients were selected as the research subjects.Based on the random number table method,the patients were divided into an observation group and a control group,with 50 patients in each group.The control group received conventional treatment,while the observation group received conventional treatment+vericiguat tablets.Comparison of therapeutic effect,the parameters of cardiopulmonary exercise tests[maximum oxygen uptake(VO_(2max)),anaerobic threshold(AT),and peak oxygen pulse(Peak VO2/HR)],cardiac function[left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT proBNP),left ventricular end diastolic diameter(LVEDD)],and occurrence of adverse events between the two groups.Results After treatment,the total effective rate of 96.00%(48/50)in the observation group was significantly higher than 78.00%(39/50)in the control group,and there was significant statistical difference(P<0.05).After treatment,the observation group had VO_(2max) of(22.26±1.41)ml/(kg·min)and AT of(869.37±102.64)ml/min,which were higher than(17.32±1.18)ml/(kg·min)and(735.41±86.25)ml/min in the control group;the observation group had lower Peak VO2/HR of(8.93±0.76)ml/beat than(11.34±1.02)ml/beat in the control group;there was significant statistical difference(P<0.05).The observation group had significantly higher LVEF of(48.94±3.53)%than(42.15±3.44)%in the control group;the observation group had NT-proBNP of(1145.47±85.02)pg/ml and LVEDD of(51.54±7.19)mm,which were significantly lower than(1896.16±93.14)pg/ml and(57.15±7.76)mm in the control group;there was significant statistical difference(P<0.05).The incidence of adverse events of 4.00%(2/50)in the observation group was significantly lower than 18.00%(9/50)in the control group,and there was significant statistical difference(P

关 键 词：可溶性鸟苷酸环化酶激动剂 维立西呱片 射血分数降低的心力衰竭 心肺运动试验 

分 类 号：R541.6[医药卫生—心血管疾病]